Stockreport

Why Rapport Therapeutics (RAPP) Is Up 6.3% After Positive Phase 2a Epilepsy Drug Results and Analyst Optimism [Yahoo! Finance]

Rapport Therapeutics, Inc.  (RAPP) 
PDF This milestone attracted renewed analyst optimism, highlighting the significant commercial potential for RAP-219 in central nervous system disorders. We'll examine ho [Read more]